Skip to main content

letter

. 1978 Oct 14;2(6144):1089–1090. doi: 10.1136/bmj.2.6144.1089-d

Razoxane in treatment of acute myeloid leukaemia.

D Shaw, G R Tudhope

PMCID: PMC1608192 PMID: 280401

1089

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Burge P. S., Prankerd T. A., Richards J. D., Sare M., Thompson D. S., Wright P. Quality and quantity of survival in acute myeloid leukaemia. Lancet. 1975 Oct 4;2(7936):621–624. doi: 10.1016/s0140-6736(75)90111-7. [DOI] [PubMed] [Google Scholar]
Gale R. P., Cline M. J. High remission-induction rate in acute myeloid leukaemia. Lancet. 1977 Mar 5;1(8010):497–499. doi: 10.1016/s0140-6736(77)91366-6. [DOI] [PubMed] [Google Scholar]
Rees J. K., Sandler R. M., Challener J., Hayhoe F. G. Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT. Br J Cancer. 1977 Dec;36(6):770–776. doi: 10.1038/bjc.1977.260. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES